Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
October 6, 2022

Eiger shuns plans to seek EUA from US FDA for Covid-19 treatment

Eiger BioPharmaceuticals has announced that it will not seek emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for peginterferon lambda to treat mild-to-moderate Covid-19 patients.

Eiger is looking for strategic options to continue peginterferon lambda development for Covid-19 and other respiratory viral infections. Credit: PIRO from Pixabay.